Quick Answer
Neumora Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $182.53 million for the year ending 2025.
- Neumora Therapeutics, Inc. showed an increase of +28.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $252.51 million | Q1 2023: $210.87 million | Q2 2023: $204.22 million | Q3 2023: $412.28 million | Q1 2024: $182.93 million | Q2 2024: $150.68 million | Q3 2024: $275.71 million | Q1 2025: $126.86 million | Q2 2025: $124.52 million | Q3 2025: $129.07 million.
- Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 24.2%.
- Historical annual values: Fiscal year 2025: $182.53 million | Fiscal year 2024: $142.15 million | Fiscal year 2023: $374.04 million | Fiscal year 2022: $240.94 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: